Alpha Versus Beta: Tumor Architecture Decides Where Radiation Dose Lands

When doctors treat cancer with radiopharmaceutical therapy, they inject radioactive molecules that seek out tumor cells and destroy them from within. But a persistent gap separates what can actually be measured in a patient and what happens at the scale where the biology unfolds. Gamma camera imaging, the practical workhorse of patient dosimetry, resolves distances far larger than the micrometer ranges over which therapeutic radiation deposits its energy. A new modeling study published in EJNMMI Physics on 25 October 2026 tackles that mismatch head-on, using multiscale Monte Carlo simulations to trace how two clinically important radionuclides, the beta-emitter lutetium-177 and the alpha-emitter astatine-211, distribute their dose across tumor microarchitectures of very different kinds.

The problem the researchers set out to quantify is fundamental. Beta particles emitted by lutetium-177 travel hundreds of micrometers and carry low linear energy transfer, which means neighboring cells irradiate one another through so-called cross-fire. Alpha particles from astatine-211 behave almost oppositely: they deposit energy over only tens of micrometers, with linear energy transfer values two to three orders of magnitude higher than beta particles. That contrast matters most in tumors or normal organs that express the molecular target unevenly, because the true microdistribution of the radiopharmaceutical may be hidden entirely beneath the coarse resolution of planar imaging.

At the single-cell level, the simulations produced a striking number. The self-dose to the nucleus per decay was approximately 120-fold higher for astatine-211 than for lutetium-177, a direct consequence of the alpha particle’s higher linear energy transfer. In other words, a single astatine decay delivers vastly more energy to the cell that contains it, while a lutetium decay spreads its energy thinly across many neighbors.

Scale, however, changes the picture dramatically. Energy confinement analysis showed that more than 90 percent of astatine-211 emission energy was absorbed within spherical micrometastases larger than roughly 300 micrometers. Lutetium-177, by contrast, needed tumor dimensions on the millimeter scale to approach similar energy retention.

The team then extended the modeling from single cells to multicellular clusters, and here the results became strongly dependent on two variables: the spacing between cells and the fraction of cells actually labeled by the radiopharmaceutical. Increasing cell separation and decreasing the targeting fraction both produced progressively greater dose heterogeneity. The effect was particularly pronounced for astatine-211, where dose delivery became dominated by self-dose with minimal cross-fire contributions. In practical terms, an alpha-emitter hitting only some cells in a dispersed tumor leaves the unlabeled cells largely untouched, whereas a beta-emitter still bathes them through cross-fire.

That sensitivity to incomplete targeting is the study’s central caution. Astatine-211 delivers highly localized irradiation to the cells it reaches, which is precisely what makes alpha therapy attractive for killing targeted cells efficiently. But in dispersed tumor architectures where the targeting fraction is low, that same localization becomes a liability, because the dose never reaches the cells the radiopharmaceutical missed. Lutetium-177 provides broader cross-fire dose coverage, at the price of a much lower absorbed dose per decay.

The authors’ conclusion is that radionuclide emission physics and tumor microarchitecture jointly determine absorbed dose distributions in radiopharmaceutical therapy, and that neither can be considered in isolation. Optimizing treatment strategies, they argue, requires integrating the emission characteristics of the radionuclide with the characteristics of the tumor microenvironment, including intercellular spacing and the heterogeneity of molecular target expression.

For the field, the work offers a quantitative framework for a question that gamma camera dosimetry cannot answer on its own: how much of the biologically relevant dose heterogeneity is invisible at clinically measurable resolutions. The findings are computational, drawn from Monte Carlo modeling across defined microarchitectures rather than from patient measurements, and the article is being shared early as a peer-reviewed, accepted manuscript that remains subject to further edits before the final version of record. Even so, the message is clear. Choosing between an alpha-emitter and a beta-emitter is not simply a choice between high and low linear energy transfer; it is a choice that should be matched to how tightly packed the tumor cells are and how completely the radiopharmaceutical can find them.

Subject of Research: Multiscale Monte Carlo dosimetry comparing 177Lu and 211At dose distributions across tumor microarchitectures

Article Title: Multiscale Monte Carlo-based dosimetry of 177Lu and 211At across distinct tumor microarchitectures

Article References: Velo, A. F., O’Donoghue, J., Carter, L., Lerner, E., Bodei, L., & Humm, J. L. (2026). Multiscale Monte Carlo-based dosimetry of 177Lu and 211At across distinct tumor microarchitectures. EJNMMI Physics. https://doi.org/10.1186/s40658-026-00961-6

Image Credits: AI Generated

DOI: 10.1186/s40658-026-00961-6

Keywords: radiopharmaceutical therapy, dosimetry, Monte Carlo simulation, astatine-211, lutetium-177, alpha emitters, beta emitters, tumor microarchitecture, cross-fire radiation, linear energy transfer, micrometastases, EJNMMI Physics